Global Minimal Residual Disease (MRD) Testing Market Outlook, 2030
The global minimal residual disease (MRD) testing market will reach $2.86B, fueled by advancements in cancer diagnostics.
- Bonafide Trust
- 21-03-2025
- Pages : 170
- Region : Global
- Category : Lifescience & Healthcare
- Healthcare
The global Minimal Residual Disease (MRD) testing market is experiencing significant growth, driven by the increasing prevalence of cancer and the rising adoption of personalized medicine. MRD testing plays a crucial role in cancer management by detecting minimal levels of residual cancer cells after treatment, providing valuable insights into the risk of relapse and guiding treatment decisions. The market is witnessing a surge in demand for advanced MRD testing technologies, such as next-generation sequencing (NGS) and digital PCR, which offer higher sensitivity and accuracy compared to traditional methods. The growing awareness of MRD testing among healthcare professionals and patients, coupled with increasing investments in research and development, are further fueling market expansion. Additionally, the rising adoption of MRD testing in clinical trials for new cancer therapies is contributing to the market's growth. The market is also being propelled by the increasing availability of MRD testing services and the expanding applications of MRD testing in various cancer types, including hematological malignancies and solid tumors. Moreover, the growing focus on early cancer detection and prevention is expected to create lucrative opportunities for the MRD testing market in the coming years. The market is characterized by intense competition among key players, who are focusing on developing innovative MRD testing solutions and expanding their global presence. The market is also witnessing a trend of strategic collaborations and partnerships among market players to enhance their product offerings and market reach. The MRD testing market is poised for robust growth in the forecast period, driven by the increasing demand for personalized cancer care and the continuous advancements in MRD testing technologies.
Global minimal residual disease (MRD) testing market will reach $2,858.1 million by 2031, growing by 12.4% annually over 2021-2031, driven by the rising prevalence of hematological malignancy and cancer, the aging population, technological advancements in diagnostics and therapies due to increasing R&D investment, and the growing healthcare expenditure. The global Minimal Residual Disease (MRD) testing market is witnessing several key trends, including the increasing adoption of NGS-based MRD testing, the growing use of liquid biopsies for MRD detection, and the rising demand for point-of-care MRD testing solutions. NGS technology offers high sensitivity and accuracy in detecting MRD, making it a preferred choice for MRD testing. Liquid biopsies, which involve the analysis of circulating tumor DNA (ctDNA) in blood samples, are gaining popularity as a non-invasive alternative to traditional tissue biopsies for MRD detection. The demand for point-of-care MRD testing solutions is increasing due to their ability to provide rapid and convenient results, enabling timely treatment decisions. The MRD testing market is driven by several factors, including the increasing prevalence of cancer, the rising adoption of personalized medicine, and the growing awareness of MRD testing among healthcare professionals and patients. The increasing availability of MRD testing services and the expanding applications of MRD testing in various cancer types are also contributing to market growth. Additionally, the rising investments in research and development for MRD testing technologies and the increasing adoption of MRD testing in clinical trials are fueling market expansion. The MRD testing market is also influenced by various trade programs, such as government initiatives to promote cancer screening and early detection, reimbursement policies for MRD testing, and regulatory approvals for new MRD testing products. These programs play a crucial role in shaping the market dynamics and influencing the adoption of MRD testing.
What's Inside a Bonafide Research`s industry report?
A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.
Download SampleThe global Minimal Residual Disease (MRD) testing market is segmented by offering into assays and reagents, instruments, software, and services. The assays and reagents segment dominates the market, driven by the recurring need for these consumables in MRD testing. The instruments segment is also witnessing significant growth, fueled by the increasing demand for advanced MRD testing platforms, such as NGS systems and digital PCR instruments. The software segment is gaining traction, with the growing need for sophisticated data analysis and interpretation tools for MRD testing. The services segment is expanding, driven by the increasing outsourcing of MRD testing services by healthcare providers and research institutions. The offering segment is further categorized by product type, such as PCR-based assays, NGS-based assays, flow cytometry-based assays, and others. The PCR-based assays segment holds the largest market share, owing to the widespread use of PCR technology in MRD testing. However, the NGS-based assays segment is expected to witness the highest growth rate in the forecast period, driven by the increasing adoption of NGS technology for MRD detection. The offering segment is also characterized by the presence of various market players, ranging from established companies to emerging players. These players are focusing on developing innovative MRD testing products and expanding their product portfolios to cater to the diverse needs of the market. The offering segment is crucial for the growth of the MRD testing market, as it provides the necessary tools and resources for MRD detection and analysis.
The global Minimal Residual Disease (MRD) testing market is segmented by application into hematological malignancies, solid tumors, and others. The hematological malignancies segment dominates the market, driven by the widespread use of MRD testing in the management of leukemia, lymphoma, and myeloma. The solid tumors segment is also witnessing significant growth, fueled by the increasing adoption of MRD testing in various solid tumor types, such as breast cancer, lung cancer, and colorectal cancer. The others segment includes applications of MRD testing in other areas, such as minimal persistent disease (MPD) monitoring and companion diagnostics. The application segment is further categorized by disease type, such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), multiple myeloma, and others. The AML segment holds the largest market share, owing to the high prevalence of AML and the well-established role of MRD testing in AML management. However, the other segments are also expected to witness significant growth in the forecast period, driven by the increasing adoption of MRD testing in various hematological malignancies and solid tumors. The application segment is crucial for the growth of the MRD testing market, as it defines the specific areas where MRD testing is utilized and drives the demand for MRD testing products and services.
The global Minimal Residual Disease (MRD) testing market is segmented by technology into polymerase chain reaction (PCR), next-generation sequencing (NGS), flow cytometry, and others. The PCR segment holds the largest market share, owing to the widespread use of PCR technology in MRD testing. PCR is a well-established and cost-effective technology for MRD detection, making it a popular choice among healthcare providers. However, the NGS segment is expected to witness the highest growth rate in the forecast period, driven by the increasing adoption of NGS technology for MRD detection. NGS offers higher sensitivity and accuracy compared to PCR, enabling the detection of MRD at lower levels. The flow cytometry segment is also witnessing significant growth, fueled by the increasing use of flow cytometry in MRD testing for hematological malignancies. The others segment includes other technologies used in MRD testing, such as digital PCR and droplet digital PCR. The technology segment is crucial for the growth of the MRD testing market, as it determines the methods and tools used for MRD detection and analysis. The continuous advancements in MRD testing technologies are driving the market's growth and enabling more accurate and sensitive MRD detection.
The global Minimal Residual Disease (MRD) testing market is segmented by end user into hospitals and specialty clinics, diagnostic laboratories, and others. The hospitals and specialty clinics segment dominates the market, driven by the high volume of MRD testing performed in these settings. Hospitals and specialty clinics are equipped with the necessary infrastructure and expertise to conduct MRD testing, making them a primary end user of MRD testing products and services. The diagnostic laboratories segment is also witnessing significant growth, fueled by the increasing outsourcing of MRD testing services by healthcare providers. Diagnostic laboratories offer specialized MRD testing services and cater to the needs of various healthcare providers. The others segment includes other end users of MRD testing, such as research institutions and pharmaceutical companies. The end user segment is crucial for the growth of the MRD testing market, as it identifies the key customers and their specific needs. The market players are focusing on catering to the diverse needs of different end users by offering tailored MRD testing solutions and services.
The global Minimal Residual Disease (MRD) testing market is segmented by region into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America 1 dominates the market, driven by the high prevalence of cancer, the presence of advanced healthcare infrastructure, and the increasing adoption of MRD testing in the region. Europe is also a significant market for MRD testing, owing to the growing awareness of MRD testing and the increasing investments in healthcare. Asia Pacific is expected to witness the highest growth rate in the forecast period, driven by the rising prevalence of cancer, the increasing healthcare expenditure, and the growing adoption of MRD testing in the region. Latin America and Middle East & Africa are also expected to witness significant growth in the MRD testing market, fueled by the increasing awareness of MRD testing and the improving healthcare infrastructure in these regions. The region segment is crucial for the growth of the MRD testing market, as it highlights the geographical distribution of the market and the specific factors influencing market growth in different regions. The market players are focusing on expanding their presence in different regions by offering tailored MRD testing solutions and services to meet the specific needs of each region.
Table of Contents
- 1 Introduction 9
- 1.1 Industry Definition and Research Scope 9
- 1.1.1 Industry Definition 9
- 1.1.2 Research Scope 10
- 1.2 Research Methodology 13
- 1.2.1 Overview of Market Research Methodology 13
- 1.2.2 Market Assumption 14
- 1.2.3 Secondary Data 14
- 1.2.4 Primary Data 14
- 1.2.5 Data Filtration and Model Design 15
- 1.2.6 Market Size/Share Estimation 16
- 1.2.7 Research Limitations 17
- 1.3 Executive Summary 18
- 2 Market Overview and Dynamics 21
- 2.1 Market Size and Forecast 21
- 2.1.1 Impact of COVID-19 on World Economy 22
- 2.1.2 Impact of COVID-19 on the Market 24
- 2.2 Major Growth Drivers 26
- 2.3 Market Restraints and Challenges 32
- 2.4 Emerging Opportunities and Market Trends 35
- 2.5 Porter’s Fiver Forces Analysis 39
- 3 Segmentation of Global Market by Offering 43
- 3.1 Market Overview by Offering 43
- 3.2 Services 45
- 3.3 Test Kits & Consumables 46
- 4 Segmentation of Global Market by Application 47
- 4.1 Market Overview by Application 47
- 4.2 Non-Hodgkin’s Lymphoma (NHL) 49
- 4.2.1 DLBCL 51
- 4.2.2 Marginal Zone Lymphoma 52
- 4.2.3 Follicular Lymphoma 53
- 4.2.4 Peripheral T-cell Lymphoma 54
- 4.2.5 Mantle Cell Lymphoma 55
- 4.2.6 Other NHLs 56
- 4.3 Multiple Myeloma (MM) 57
- 4.4 Acute Lymphoblastic Leukemia (ALL) 58
- 4.5 Chronic Lymphoblastic Leukemia (CLL) 59
- 4.6 Acute Myeloid Leukemia (AML) 60
- 4.7 Chronic Myeloid Leukemia (CML) 61
- 4.8 Hodgkin’s Lymphoma (HL) 62
- 4.9 Solid Tumor 63
- 4.10 Other Applications 64
- 5 Segmentation of Global Market by Technology 65
- 5.1 Market Overview by Technology 65
- 5.2 Flow Cytometry 67
- 5.3 Polymerase Chain Reaction (PCR) 68
- 5.4 Next-Generation Sequencing (NGS) 69
- 5.5 Other Technologies 70
- 6 Segmentation of Global Market by End User 71
- 6.1 Market Overview by End User 71
- 6.2 Hospitals and Clinics 73
- 6.3 Research Institutions 74
- 6.4 Diagnostic Laboratories 75
- 6.5 Other End Users 76
- 7 Segmentation of Global Market by Region 77
- 7.1 Geographic Market Overview 2021-2031 77
- 7.2 North America Market 2021-2031 by Country 81
- 7.2.1 Overview of North America Market 81
- 7.2.2 U.S. 85
- 7.2.3 Canada 88
- 7.2.4 Mexico 90
- 7.3 European Market 2021-2031 by Country 92
- 7.3.1 Overview of European Market 92
- 7.3.2 Germany 96
- 7.3.3 U.K. 98
- 7.3.4 France 100
- 7.3.5 Spain 102
- 7.3.6 Italy 104
- 7.3.7 Netherlands 106
- 7.3.8 Rest of European Market 108
- 7.4 Asia-Pacific Market 2021-2031 by Country 110
- 7.4.1 Overview of Asia-Pacific Market 110
- 7.4.2 Japan 114
- 7.4.3 China 117
- 7.4.4 Australia 119
- 7.4.5 India 121
- 7.4.6 South Korea 123
- 7.4.7 Rest of APAC Region 125
- 7.5 South America Market 2021-2031 by Country 127
- 7.5.1 Argentina 130
- 7.5.2 Brazil 132
- 7.5.3 Chile 134
- 7.5.4 Rest of South America Market 136
- 7.6 MEA Market 2021-2031 by Country 137
- 7.6.1 UAE 140
- 7.6.2 Saudi Arabia 142
- 7.6.3 South Africa 144
- 7.6.4 Other National Markets 146
- 8 Competitive Landscape 147
- 8.1 Overview of Key Vendors 147
- 8.2 New Product Launch, Partnership, Investment, and M&A 151
- 8.3 Company Profiles 152
- Adaptive Biotechnologies Corporation 152
- ArcherDX, Inc. (Invitae Corporation) 154
- Arup Laboratories 155
- Asuragen Inc. 156
- Bio-Rad Laboratories, Inc. 157
- Cergentis B.V. 158
- Guardant Health 159
- ICON plc 160
- Inivata Ltd. 161
- Invivoscribe, Inc. 162
- Laboratory Corporation of America Holdings 163
- Mission Bio, Inc. 164
- Natera, Inc. 165
- NeoGenomics Laboratories, Inc. 166
- Opko Health, Inc. 167
- Quest Diagnostics Incorporated 168
- Sysmex Corporation 169
- RELATED REPORTS 170
List of Tables:
Table 1. Snapshot of Global Minimal Residual Disease Testing Market in Balanced Perspective, 2021-2031 19
Table 2. World Economic Outlook, 2021-2031 23
Table 3. World Health Spending by Region, $ bn, 2013-2020 31
Table 4. Main Product Trends and Market Opportunities in Global Minimal Residual Disease Testing Market 35
Table 5. Global Minimal Residual Disease Testing Market by Offering, 2021-2031, $ mn 43
Table 6. Global Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 47
Table 7. Global Minimal Residual Disease Testing Market: Non-Hodgkin’s Lymphoma (NHL) by Type, 2021-2031, $ mn 50
Table 8. Global Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 65
Table 9. Main Vendors and Products of Flow Cytometry Technology 67
Table 10. Main Vendors and Products of Polymerase Chain Reaction (PCR) Technology 68
Table 11. Main Vendors and Products of Next-Generation Sequencing (NGS) Technology 69
Table 12. Global Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 71
Table 13. Global Minimal Residual Disease Testing Market by Region, 2021-2031, $ mn 78
Table 14. Leading National Minimal Residual Disease Testing Market, 2021 and 2031, $ mn 80
Table 15. North America Minimal Residual Disease Testing Market by Country, 2021-2031, $ mn 83
Table 16. U.S. Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 87
Table 17. U.S. Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 87
Table 18. U.S. Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 87
Table 19. Canada Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 89
Table 20. Canada Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 89
Table 21. Canada Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 89
Table 22. Mexico Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 91
Table 23. Mexico Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 91
Table 24. Mexico Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 91
Table 25. Europe Minimal Residual Disease Testing Market by Country, 2021-2031, $ mn 95
Table 26. Germany Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 97
Table 27. Germany Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 97
Table 28. Germany Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 97
Table 29. U.K. Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 99
Table 30. U.K. Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 99
Table 31. U.K. Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 99
Table 32. France Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 101
Table 33. France Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 101
Table 34. France Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 101
Table 35. Spain Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 103
Table 36. Spain Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 103
Table 37. Spain Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 103
Table 38. Italy Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 105
Table 39. Italy Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 105
Table 40. Italy Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 105
Table 41. Netherlands Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 107
Table 42. Netherlands Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 107
Table 43. Netherlands Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 107
Table 44. Minimal Residual Disease Testing Market in Rest of Europe by Country, 2021-2031, $ mn 109
Table 45. APAC Minimal Residual Disease Testing Market by Country, 2021-2031, $ mn 112
Table 46. Japan Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 116
Table 47. Japan Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 116
Table 48. Japan Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 116
Table 49. China Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 118
Table 50. China Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 118
Table 51. China Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 118
Table 52. Australia Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 120
Table 53. Australia Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 120
Table 54. Australia Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 120
Table 55. India Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 122
Table 56. India Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 122
Table 57. India Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 122
Table 58. South Korea Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 124
Table 59. South Korea Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 124
Table 60. South Korea Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 124
Table 61. Minimal Residual Disease Testing Market in Rest of APAC by Country/Region, 2021-2031, $ mn 126
Table 62. South America Minimal Residual Disease Testing Market by Country, 2021-2031, $ mn 129
Table 63. Argentina Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 131
Table 64. Argentina Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 131
Table 65. Argentina Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 131
Table 66. Brazil Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 133
Table 67. Brazil Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 133
Table 68. Brazil Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 133
Table 69. Chile Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 135
Table 70. Chile Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 135
Table 71. Chile Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 135
Table 72. MEA Minimal Residual Disease Testing Market by Country, 2021-2031, $ mn 139
Table 73. UAE Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 141
Table 74. UAE Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 141
Table 75. UAE Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 141
Table 76. Saudi Arabia Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 143
Table 77. Saudi Arabia Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 143
Table 78. Saudi Arabia Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 143
Table 79. South Africa Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 145
Table 80. South Africa Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 145
Table 81. South Africa Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 145
Table 82. Breakdown of World Market by Key Vendor, 2021, % 149
Table 83. Approved and Launched MRD Testing Products of Key Vendors 149
Table 84. Adaptive Biotechnologies Corporation: Company Snapshot 152
Table 85. Adaptive Biotechnologies Corporation: Business Segmentation 153
Table 86. Adaptive Biotechnologies Corporation: Product Portfolio 153
Table 1. Snapshot of Global Minimal Residual Disease Testing Market in Balanced Perspective, 2021-2031 19
Table 2. World Economic Outlook, 2021-2031 23
Table 3. World Health Spending by Region, $ bn, 2013-2020 31
Table 4. Main Product Trends and Market Opportunities in Global Minimal Residual Disease Testing Market 35
Table 5. Global Minimal Residual Disease Testing Market by Offering, 2021-2031, $ mn 43
Table 6. Global Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 47
Table 7. Global Minimal Residual Disease Testing Market: Non-Hodgkin’s Lymphoma (NHL) by Type, 2021-2031, $ mn 50
Table 8. Global Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 65
Table 9. Main Vendors and Products of Flow Cytometry Technology 67
Table 10. Main Vendors and Products of Polymerase Chain Reaction (PCR) Technology 68
Table 11. Main Vendors and Products of Next-Generation Sequencing (NGS) Technology 69
Table 12. Global Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 71
Table 13. Global Minimal Residual Disease Testing Market by Region, 2021-2031, $ mn 78
Table 14. Leading National Minimal Residual Disease Testing Market, 2021 and 2031, $ mn 80
Table 15. North America Minimal Residual Disease Testing Market by Country, 2021-2031, $ mn 83
Table 16. U.S. Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 87
Table 17. U.S. Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 87
Table 18. U.S. Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 87
Table 19. Canada Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 89
Table 20. Canada Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 89
Table 21. Canada Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 89
Table 22. Mexico Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 91
Table 23. Mexico Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 91
Table 24. Mexico Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 91
Table 25. Europe Minimal Residual Disease Testing Market by Country, 2021-2031, $ mn 95
Table 26. Germany Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 97
Table 27. Germany Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 97
Table 28. Germany Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 97
Table 29. U.K. Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 99
Table 30. U.K. Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 99
Table 31. U.K. Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 99
Table 32. France Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 101
Table 33. France Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 101
Table 34. France Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 101
Table 35. Spain Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 103
Table 36. Spain Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 103
Table 37. Spain Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 103
Table 38. Italy Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 105
Table 39. Italy Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 105
Table 40. Italy Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 105
Table 41. Netherlands Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 107
Table 42. Netherlands Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 107
Table 43. Netherlands Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 107
Table 44. Minimal Residual Disease Testing Market in Rest of Europe by Country, 2021-2031, $ mn 109
Table 45. APAC Minimal Residual Disease Testing Market by Country, 2021-2031, $ mn 112
Table 46. Japan Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 116
Table 47. Japan Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 116
Table 48. Japan Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 116
Table 49. China Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 118
Table 50. China Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 118
Table 51. China Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 118
Table 52. Australia Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 120
Table 53. Australia Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 120
Table 54. Australia Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 120
Table 55. India Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 122
Table 56. India Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 122
Table 57. India Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 122
Table 58. South Korea Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 124
Table 59. South Korea Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 124
Table 60. South Korea Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 124
Table 61. Minimal Residual Disease Testing Market in Rest of APAC by Country/Region, 2021-2031, $ mn 126
Table 62. South America Minimal Residual Disease Testing Market by Country, 2021-2031, $ mn 129
Table 63. Argentina Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 131
Table 64. Argentina Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 131
Table 65. Argentina Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 131
Table 66. Brazil Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 133
Table 67. Brazil Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 133
Table 68. Brazil Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 133
Table 69. Chile Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 135
Table 70. Chile Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 135
Table 71. Chile Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 135
Table 72. MEA Minimal Residual Disease Testing Market by Country, 2021-2031, $ mn 139
Table 73. UAE Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 141
Table 74. UAE Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 141
Table 75. UAE Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 141
Table 76. Saudi Arabia Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 143
Table 77. Saudi Arabia Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 143
Table 78. Saudi Arabia Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 143
Table 79. South Africa Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 145
Table 80. South Africa Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 145
Table 81. South Africa Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 145
Table 82. Breakdown of World Market by Key Vendor, 2021, % 149
Table 83. Approved and Launched MRD Testing Products of Key Vendors 149
Table 84. Adaptive Biotechnologies Corporation: Company Snapshot 152
Table 85. Adaptive Biotechnologies Corporation: Business Segmentation 153
Table 86. Adaptive Biotechnologies Corporation: Product Portfolio 153
List of Figures:
Figure 1. Research Method Flow Chart 13
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 16
Figure 3. Global Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2021-2031 18
Figure 4. Global Minimal Residual Disease Testing Market, 2021-2031, $ mn 21
Figure 5. Impact of COVID-19 on Business 24
Figure 6. Primary Drivers and Impact Factors of Global Minimal Residual Disease Testing Market 26
Figure 7. World Number of Deaths from Cancers in 201 29
Figure 8. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 30
Figure 9. World Population 65 and Over, % of Total Population, 1950-2060 30
Figure 10. Primary Restraints and Impact Factors of Global Minimal Residual Disease Testing Market 32
Figure 11. Investment Opportunity Analysis 36
Figure 12. Porter’s Fiver Forces Analysis of Global Minimal Residual Disease Testing Market 39
Figure 13. Breakdown of Global Minimal Residual Disease Testing Market by Offering, 2021-2031, % of Revenue 44
Figure 14. Global Addressable Market Cap in 2022-2031 by Offering, Value ($ mn) and Share (%) 44
Figure 15. Global Minimal Residual Disease Testing Market by Offering: Services, 2021-2031, $ mn 45
Figure 16. Global Minimal Residual Disease Testing Market by Offering: Test Kits & Consumables, 2021-2031, $ mn 46
Figure 17. Breakdown of Global Minimal Residual Disease Testing Market by Application, 2021-2031, % of Sales Revenue 48
Figure 18. Global Addressable Market Cap in 2022-2031 by Application, Value ($ mn) and Share (%) 48
Figure 19. Global Minimal Residual Disease Testing Market by Application: Non-Hodgkin’s Lymphoma (NHL), 2021-2031, $ mn 49
Figure 20. Global Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): DLBCL, 2021-2031, $ mn 51
Figure 21. Global Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Marginal Zone Lymphoma, 2021-2031, $ mn 52
Figure 22. Global Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Follicular Lymphoma, 2021-2031, $ mn 53
Figure 23. Global Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Peripheral T-cell Lymphoma, 2021-2031, $ mn 54
Figure 24. Global Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Mantle Cell Lymphoma, 2021-2031, $ mn 55
Figure 25. Global Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Other NHLs, 2021-2031, $ mn 56
Figure 26. Global Minimal Residual Disease Testing Market by Application: Multiple Myeloma (MM), 2021-2031, $ mn 57
Figure 27. Global Minimal Residual Disease Testing Market by Application: Acute Lymphoblastic Leukemia (ALL), 2021-2031, $ mn 58
Figure 28. Global Minimal Residual Disease Testing Market by Application: Chronic Lymphoblastic Leukemia (CLL), 2021-2031, $ mn 59
Figure 29. Global Minimal Residual Disease Testing Market by Application: Acute Myeloid Leukemia (AML), 2021-2031, $ mn 60
Figure 30. Global Minimal Residual Disease Testing Market by Application: Chronic Myeloid Leukemia (CML), 2021-2031, $ mn 61
Figure 31. Global Minimal Residual Disease Testing Market by Application: Hodgkin’s Lymphoma (HL), 2021-2031, $ mn 62
Figure 32. Global Minimal Residual Disease Testing Market by Application: Solid Tumor, 2021-2031, $ mn 63
Figure 33. Global Minimal Residual Disease Testing Market by Application: Other Applications, 2021-2031, $ mn 64
Figure 34. Breakdown of Global Minimal Residual Disease Testing Market by Technology, 2021-2031, % of Sales Revenue 66
Figure 35. Global Addressable Market Cap in 2022-2031 by Technology, Value ($ mn) and Share (%) 66
Figure 36. Global Minimal Residual Disease Testing Market by Technology: Flow Cytometry, 2021-2031, $ mn 67
Figure 37. Global Minimal Residual Disease Testing Market by Technology: Polymerase Chain Reaction (PCR), 2021-2031, $ mn 68
Figure 38. Global Minimal Residual Disease Testing Market by Technology: Next-Generation Sequencing (NGS), 2021-2031, $ mn 69
Figure 39. Global Minimal Residual Disease Testing Market by Technology: Other Technologies, 2021-2031, $ mn 70
Figure 40. Breakdown of Global Minimal Residual Disease Testing Market by End User, 2021-2031, % of Revenue 72
Figure 41. Global Addressable Market Cap in 2022-2031 by End User, Value ($ mn) and Share (%) 72
Figure 42. Global Minimal Residual Disease Testing Market by End User: Hospitals and Clinics, 2021-2031, $ mn 73
Figure 43. Global Minimal Residual Disease Testing Market by End User: Research Institutions, 2021-2031, $ mn 74
Figure 44. Global Minimal Residual Disease Testing Market by End User: Diagnostic Laboratories, 2021-2031, $ mn 75
Figure 45. Global Minimal Residual Disease Testing Market by End User: Other End Users, 2021-2031, $ mn 76
Figure 46. Global Market Snapshot by Region 77
Figure 47. Geographic Spread of Worldwide Minimal Residual Disease Testing Market, 2021-2031, % of Sales Revenue 78
Figure 48. Global Addressable Market Cap in 2022-2031 by Region, Value ($ mn) and Share (%) 79
Figure 49. North American Minimal Residual Disease Testing Market, 2021-2031, $ mn 82
Figure 50. Breakdown of North America Minimal Residual Disease Testing Market by Country, 2021 and 2031, % of Revenue 83
Figure 51. Contribution to North America 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%) 84
Figure 52. U.S. Minimal Residual Disease Testing Market, 2021-2031, $ mn 86
Figure 53. Canada Minimal Residual Disease Testing Market, 2021-2031, $ mn 88
Figure 54. Minimal Residual Disease Testing Market in Mexico, 2021-2031, $ mn 90
Figure 55. European Minimal Residual Disease Testing Market, 2021-2031, $ mn 93
Figure 56. Breakdown of European Minimal Residual Disease Testing Market by Country, 2021 and 2031, % of Revenue 94
Figure 57. Contribution to Europe 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%) 95
Figure 58. Minimal Residual Disease Testing Market in Germany, 2021-2031, $ mn 96
Figure 59. Minimal Residual Disease Testing Market in U.K., 2021-2031, $ mn 98
Figure 60. Minimal Residual Disease Testing Market in France, 2021-2031, $ mn 100
Figure 61. Minimal Residual Disease Testing Market in Spain, 2021-2031, $ mn 102
Figure 62. Minimal Residual Disease Testing Market in Italy, 2021-2031, $ mn 104
Figure 63. Minimal Residual Disease Testing Market in Netherlands, 2021-2031, $ mn 106
Figure 64. Minimal Residual Disease Testing Market in Rest of Europe, 2021-2031, $ mn 108
Figure 65. Asia-Pacific Minimal Residual Disease Testing Market, 2021-2031, $ mn 111
Figure 66. Breakdown of APAC Minimal Residual Disease Testing Market by Country, 2021 and 2031, % of Revenue 111
Figure 67. Contribution to APAC 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%) 113
Figure 68. Minimal Residual Disease Testing Market in Japan, 2021-2031, $ mn 115
Figure 69. Minimal Residual Disease Testing Market in China, 2021-2031, $ mn 117
Figure 70. Minimal Residual Disease Testing Market in Australia, 2021-2031, $ mn 119
Figure 71. Minimal Residual Disease Testing Market in India, 2021-2031, $ mn 121
Figure 72. Minimal Residual Disease Testing Market in South Korea, 2021-2031, $ mn 123
Figure 73. Minimal Residual Disease Testing Market in Rest of APAC, 2021-2031, $ mn 125
Figure 74. South America Minimal Residual Disease Testing Market, 2021-2031, $ mn 128
Figure 75. Breakdown of South America Minimal Residual Disease Testing Market by Country, 2021 and 2031, % of Revenue 128
Figure 76. Contribution to South America 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%) 129
Figure 77. Minimal Residual Disease Testing Market in Argentina, 2021-2031, $ mn 130
Figure 78. Minimal Residual Disease Testing Market in Brazil, 2021-2031, $ mn 132
Figure 79. Minimal Residual Disease Testing Market in Chile, 2021-2031, $ mn 134
Figure 80. Minimal Residual Disease Testing Market in Rest of South America, 2021-2031, $ mn 136
Figure 81. Minimal Residual Disease Testing Market in Middle East and Africa (MEA), 2021-2031, $ mn 138
Figure 82. Breakdown of MEA Minimal Residual Disease Testing Market by Country, 2021 and 2031, % of Revenue 138
Figure 83. Contribution to MEA 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%) 139
Figure 84. Minimal Residual Disease Testing Market in UAE, 2021-2031, $ mn 140
Figure 85. Minimal Residual Disease Testing Market in Saudi Arabia, 2021-2031, $ mn 142
Figure 86. Minimal Residual Disease Testing Market in South Africa, 2021-2031, $ mn 144
Figure 87. Growth Stage of Global Minimal Residual Disease Testing Industry over the Forecast Period 147
Figure 1. Research Method Flow Chart 13
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 16
Figure 3. Global Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2021-2031 18
Figure 4. Global Minimal Residual Disease Testing Market, 2021-2031, $ mn 21
Figure 5. Impact of COVID-19 on Business 24
Figure 6. Primary Drivers and Impact Factors of Global Minimal Residual Disease Testing Market 26
Figure 7. World Number of Deaths from Cancers in 201 29
Figure 8. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 30
Figure 9. World Population 65 and Over, % of Total Population, 1950-2060 30
Figure 10. Primary Restraints and Impact Factors of Global Minimal Residual Disease Testing Market 32
Figure 11. Investment Opportunity Analysis 36
Figure 12. Porter’s Fiver Forces Analysis of Global Minimal Residual Disease Testing Market 39
Figure 13. Breakdown of Global Minimal Residual Disease Testing Market by Offering, 2021-2031, % of Revenue 44
Figure 14. Global Addressable Market Cap in 2022-2031 by Offering, Value ($ mn) and Share (%) 44
Figure 15. Global Minimal Residual Disease Testing Market by Offering: Services, 2021-2031, $ mn 45
Figure 16. Global Minimal Residual Disease Testing Market by Offering: Test Kits & Consumables, 2021-2031, $ mn 46
Figure 17. Breakdown of Global Minimal Residual Disease Testing Market by Application, 2021-2031, % of Sales Revenue 48
Figure 18. Global Addressable Market Cap in 2022-2031 by Application, Value ($ mn) and Share (%) 48
Figure 19. Global Minimal Residual Disease Testing Market by Application: Non-Hodgkin’s Lymphoma (NHL), 2021-2031, $ mn 49
Figure 20. Global Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): DLBCL, 2021-2031, $ mn 51
Figure 21. Global Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Marginal Zone Lymphoma, 2021-2031, $ mn 52
Figure 22. Global Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Follicular Lymphoma, 2021-2031, $ mn 53
Figure 23. Global Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Peripheral T-cell Lymphoma, 2021-2031, $ mn 54
Figure 24. Global Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Mantle Cell Lymphoma, 2021-2031, $ mn 55
Figure 25. Global Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Other NHLs, 2021-2031, $ mn 56
Figure 26. Global Minimal Residual Disease Testing Market by Application: Multiple Myeloma (MM), 2021-2031, $ mn 57
Figure 27. Global Minimal Residual Disease Testing Market by Application: Acute Lymphoblastic Leukemia (ALL), 2021-2031, $ mn 58
Figure 28. Global Minimal Residual Disease Testing Market by Application: Chronic Lymphoblastic Leukemia (CLL), 2021-2031, $ mn 59
Figure 29. Global Minimal Residual Disease Testing Market by Application: Acute Myeloid Leukemia (AML), 2021-2031, $ mn 60
Figure 30. Global Minimal Residual Disease Testing Market by Application: Chronic Myeloid Leukemia (CML), 2021-2031, $ mn 61
Figure 31. Global Minimal Residual Disease Testing Market by Application: Hodgkin’s Lymphoma (HL), 2021-2031, $ mn 62
Figure 32. Global Minimal Residual Disease Testing Market by Application: Solid Tumor, 2021-2031, $ mn 63
Figure 33. Global Minimal Residual Disease Testing Market by Application: Other Applications, 2021-2031, $ mn 64
Figure 34. Breakdown of Global Minimal Residual Disease Testing Market by Technology, 2021-2031, % of Sales Revenue 66
Figure 35. Global Addressable Market Cap in 2022-2031 by Technology, Value ($ mn) and Share (%) 66
Figure 36. Global Minimal Residual Disease Testing Market by Technology: Flow Cytometry, 2021-2031, $ mn 67
Figure 37. Global Minimal Residual Disease Testing Market by Technology: Polymerase Chain Reaction (PCR), 2021-2031, $ mn 68
Figure 38. Global Minimal Residual Disease Testing Market by Technology: Next-Generation Sequencing (NGS), 2021-2031, $ mn 69
Figure 39. Global Minimal Residual Disease Testing Market by Technology: Other Technologies, 2021-2031, $ mn 70
Figure 40. Breakdown of Global Minimal Residual Disease Testing Market by End User, 2021-2031, % of Revenue 72
Figure 41. Global Addressable Market Cap in 2022-2031 by End User, Value ($ mn) and Share (%) 72
Figure 42. Global Minimal Residual Disease Testing Market by End User: Hospitals and Clinics, 2021-2031, $ mn 73
Figure 43. Global Minimal Residual Disease Testing Market by End User: Research Institutions, 2021-2031, $ mn 74
Figure 44. Global Minimal Residual Disease Testing Market by End User: Diagnostic Laboratories, 2021-2031, $ mn 75
Figure 45. Global Minimal Residual Disease Testing Market by End User: Other End Users, 2021-2031, $ mn 76
Figure 46. Global Market Snapshot by Region 77
Figure 47. Geographic Spread of Worldwide Minimal Residual Disease Testing Market, 2021-2031, % of Sales Revenue 78
Figure 48. Global Addressable Market Cap in 2022-2031 by Region, Value ($ mn) and Share (%) 79
Figure 49. North American Minimal Residual Disease Testing Market, 2021-2031, $ mn 82
Figure 50. Breakdown of North America Minimal Residual Disease Testing Market by Country, 2021 and 2031, % of Revenue 83
Figure 51. Contribution to North America 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%) 84
Figure 52. U.S. Minimal Residual Disease Testing Market, 2021-2031, $ mn 86
Figure 53. Canada Minimal Residual Disease Testing Market, 2021-2031, $ mn 88
Figure 54. Minimal Residual Disease Testing Market in Mexico, 2021-2031, $ mn 90
Figure 55. European Minimal Residual Disease Testing Market, 2021-2031, $ mn 93
Figure 56. Breakdown of European Minimal Residual Disease Testing Market by Country, 2021 and 2031, % of Revenue 94
Figure 57. Contribution to Europe 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%) 95
Figure 58. Minimal Residual Disease Testing Market in Germany, 2021-2031, $ mn 96
Figure 59. Minimal Residual Disease Testing Market in U.K., 2021-2031, $ mn 98
Figure 60. Minimal Residual Disease Testing Market in France, 2021-2031, $ mn 100
Figure 61. Minimal Residual Disease Testing Market in Spain, 2021-2031, $ mn 102
Figure 62. Minimal Residual Disease Testing Market in Italy, 2021-2031, $ mn 104
Figure 63. Minimal Residual Disease Testing Market in Netherlands, 2021-2031, $ mn 106
Figure 64. Minimal Residual Disease Testing Market in Rest of Europe, 2021-2031, $ mn 108
Figure 65. Asia-Pacific Minimal Residual Disease Testing Market, 2021-2031, $ mn 111
Figure 66. Breakdown of APAC Minimal Residual Disease Testing Market by Country, 2021 and 2031, % of Revenue 111
Figure 67. Contribution to APAC 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%) 113
Figure 68. Minimal Residual Disease Testing Market in Japan, 2021-2031, $ mn 115
Figure 69. Minimal Residual Disease Testing Market in China, 2021-2031, $ mn 117
Figure 70. Minimal Residual Disease Testing Market in Australia, 2021-2031, $ mn 119
Figure 71. Minimal Residual Disease Testing Market in India, 2021-2031, $ mn 121
Figure 72. Minimal Residual Disease Testing Market in South Korea, 2021-2031, $ mn 123
Figure 73. Minimal Residual Disease Testing Market in Rest of APAC, 2021-2031, $ mn 125
Figure 74. South America Minimal Residual Disease Testing Market, 2021-2031, $ mn 128
Figure 75. Breakdown of South America Minimal Residual Disease Testing Market by Country, 2021 and 2031, % of Revenue 128
Figure 76. Contribution to South America 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%) 129
Figure 77. Minimal Residual Disease Testing Market in Argentina, 2021-2031, $ mn 130
Figure 78. Minimal Residual Disease Testing Market in Brazil, 2021-2031, $ mn 132
Figure 79. Minimal Residual Disease Testing Market in Chile, 2021-2031, $ mn 134
Figure 80. Minimal Residual Disease Testing Market in Rest of South America, 2021-2031, $ mn 136
Figure 81. Minimal Residual Disease Testing Market in Middle East and Africa (MEA), 2021-2031, $ mn 138
Figure 82. Breakdown of MEA Minimal Residual Disease Testing Market by Country, 2021 and 2031, % of Revenue 138
Figure 83. Contribution to MEA 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%) 139
Figure 84. Minimal Residual Disease Testing Market in UAE, 2021-2031, $ mn 140
Figure 85. Minimal Residual Disease Testing Market in Saudi Arabia, 2021-2031, $ mn 142
Figure 86. Minimal Residual Disease Testing Market in South Africa, 2021-2031, $ mn 144
Figure 87. Growth Stage of Global Minimal Residual Disease Testing Industry over the Forecast Period 147
Related Reports
One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. License information
One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. License information
Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. License information
All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). License information
Safe and Secure SSL Encrypted
Quick Contacts
Want to customize this report?
We offer 10% Free Customization at the time of purchase
Get Free Customization
Trusted Partners
Budget constraints? Get in touch with us for special pricing
Request DiscountOrder Detail
- Order Placed (09 May, 2026)
- Notify To Team (09 May, 2026)
- Report updation (10 May, 2026)
- Report Quality Check (10 May, 2026)
- Report Dispatch (11 May, 2026)
- Hard Copy
Recently Viewed Products
Global Minimal Residual Disease (MRD) Testing Market Outlook, 2030
We are friendly and approachable, give us a call.